Downloads   Careers   Contact     

Eris Lifesciences acquires trademark Zomelis from Novartis AG for India market


Eris Lifesciences acquires trademark Zomelis from Novartis AG for India market

Zomelis is used in the treatment of type 2 diabetes and comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors.

This is the first innovator pharmaceutical product trademark acquisition by Eris.

Press Links